Trial Profile
A study to evaluate individual patient factors as a predisposition to hepatotoxicity in metastatic renal cell carcinoma patients treated with pazopanib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- 04 Apr 2016 New trial record